Overview of Glp 1 Receptor Agonists And Diabetic Kidney Disease A Call
Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its ...
Glucagon-like peptide-1 receptor agonists ( GLP -1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD.
Key Details About Glp 1 Receptor Agonists And Diabetic Kidney Disease A Call
On top of this, sodium-glucose co-transporter 2 inhibitors along with finerenone showed an impressive ability to reduce the progression of kidney disease and cardiovascular events in diabetic patients with CKD. Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) can play a special role and could be a game changer in this field.
With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management. Among incretin-based drugs, glucagon-like peptide 1 ( GLP-1 ) receptor agonists are a promising therapeutic option for patients with diabetic kidney disease (DKD).
Useful Notes on Glp 1 Receptor Agonists And Diabetic Kidney Disease A Call
GLP -1RAs prevent albuminuria and slow the decline of renal function towards end stage renal disease in patients with diabetic kidney disease . They might be an opportunity to break the typical inflammation processes of COVID-19 disease .
Clinical trials such as SUSTAIN-6, REWIND, and FLOW provide evidence of GLP-1 receptor agonists reducing albuminuria and attenuating estimated glomerular filtration rate decline in patients with diabetic chronic kidney disease .
Overview of Glp 1 Receptor Agonists And Diabetic Kidney Disease A Call
This receptor distribution suggests that GLP-1 receptor agonists may contribute to kidney function. Emerging evidence supports the role of GLP-1 receptor agonists in chronic kidney disease (CKD), particularly for patients with diabetes. These agents may slow CKD progression by improving glycemic control, reducing albuminuria, and possibly protecting against glomerular damage through their anti ...
This article has been updated. See " Glucagon‐like peptide 1 ( GLP‐1 ) receptor agonists for people with chronic kidney disease and diabetes " in volume 2025, CD015849.
Key Details About Glp 1 Receptor Agonists And Diabetic Kidney Disease A Call
Although much attention is currently focused on the weight management potential of incretin-based medications, such as glucagon-like peptide-1 ( GLP-1 ) receptor agonists , there is also a growing focus on the effects in patients with chronic kidney disease (CKD). The US Food and Drug Administration approved the GLP-1 receptor agonist semaglutide to reduce kidney and cardiovascular risk in ...
GLP-1 RAs help slow CKD and lower heart disease risk for people with type 2 diabetes and /or obesity, but it's important to weigh risks and benefits.